Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)
China
· Delayed Price · Currency is CNY 39.96
+0.07 (0.18%)
Apr 29, 2026, 3:00 PM CST
SHA:600329 Revenue
In the year 2025, Tianjin Pharmaceutical Da Ren Tang Group Corporation had annual revenue of 4.92B CNY, down -32.70%. Tianjin Pharmaceutical Da Ren Tang Group Corporation had revenue of 1.25B in the quarter ending December 31, 2025, a decrease of -26.44%.
Revenue
4.92B
Revenue Growth
-32.70%
P/S Ratio
5.52
Revenue / Employee
1.26M
Employees
3,890
Market Cap
27.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.92B | -2.39B | -32.70% |
| Dec 31, 2024 | 7.31B | -915.58M | -11.14% |
| Dec 31, 2023 | 8.22B | -26.94M | -0.33% |
| Dec 31, 2022 | 8.25B | 1.34B | 19.42% |
| Dec 31, 2021 | 6.91B | 303.89M | 4.60% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Livzon Pharmaceutical Group | 11.71B |
| Dizal (Jiangsu) Pharmaceutical | 801.14M |
| Shijiazhuang Yiling Pharmaceutical | 6.01B |
| Hubei Jumpcan Pharmaceutical | 5.90B |
| Humanwell Healthcare (Group) | 23.96B |
| Kangmei Pharmaceutical | 5.25B |
| Zhejiang Huahai Pharmaceutical | 8.71B |
| Chengdu Kanghong Pharmaceutical Group | 4.43B |